Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common drug reverse Poison-Induced delirium? new study says yes

NCT ID NCT07545382

Symptom relief Sponsor: Alexandria University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 21, 2026 · Updated 1 time

Summary

This study tested whether rivastigmine can safely reverse delirium caused by poisoning from certain drugs like clozapine or tricyclic antidepressants. 100 patients at a poison center received rivastigmine, and doctors measured their consciousness and agitation levels. The goal was to see if the drug could help patients wake up and become calm and alert.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

100 people

The number who actually took part.

Started

Dec 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Exposure: acute exposure to anticholinergic agents (e.g., clozapine, tricyclic antidepressants). Clinical Presentation: Presence of anticholinergic delirium either hyperactive/agitated or hypoactive/CNS depression/coma). Exclusion Criteria: 1. Non-Toxic Delirium: Delirium of multifactorial origin or other medical causes (e.g., sepsis, hepatic encephalopathy, alcohol withdrawal, or metabolic disturbances). 2. Cardiac Contraindications: Baseline bradycardia, Atrioventricular (AV) block, or significant QTc prolongation. 3. Patients who experienced pulmonary aspiration as a complication of overdose, necessitating endotracheal intubation and mechanical ventilation 4. Severe Organ Impairment: Known severe renal or hepatic impairment. 5. Neurological Conditions: History of pre-existing seizure disorders or epilepsy. 6. Respiratory Conditions: Severe asthma or Chronic Obstructive Pulmonary Disease (COPD) due to the risk of bronchoconstriction. 7. Obstructions: Mechanical bowel obstruction or urinary tract obstruction. 8. Hypersensitivity: Known history of hypersensitivity to rivastigmine or other carbamates. 9. Pregnancy/Lactation: Pregnant or lactating women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anticholinergic delirium are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute tricyclic antidepressant poisoning drug psychosis drug-induced mental disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anticholinergic delirium Antipsychotic toxicity Clozapine poisoning CNS depression Hypoactive delirium Procyclidine induced delirium Tricyclic antidepressant poisoning

Contacts and locations

Locations

  • Poison Control Center (PCC), Alexandria University Main Hospital

    Alexandria, 21131, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.